Cargando…
Chronic urticaria and COVID-19 vaccination: Qatar data (preliminary report of COVAC-CU-international)
Background: It is a well-known fact that patients with chronic urticaria (CU) are not at a higher risk for a serious allergic reaction such as anaphylaxis from medications. However, there is a fear and some misconceptions regarding allergic reactions to the COVID-19 vaccine among patients and physic...
Autores principales: | Purayil, Saleema, Thalappil, Sherin, Al-Nesf, Maryam, Kocaturk, Emek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
HBKU Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340567/ https://www.ncbi.nlm.nih.gov/pubmed/35968517 http://dx.doi.org/10.5339/qmj.2022.fqac.2 |
Ejemplares similares
-
Real-world experience of the clinical effectiveness of omalizumab use in Qatar – a study protocol
por: Purayil, Saleema, et al.
Publicado: (2022) -
Selective COX-2 inhibitor continues to be a safe alternative in patients with nonselective NSAIDs hypersensitivity
por: Thalappil, Sherin, et al.
Publicado: (2022) -
Sulphamethoxazole-trimethoprim induced fixed drug eruption in a patient with Chronic Granulomatous Disease
por: Rahim Thalappil, Sherin, et al.
Publicado: (2022) -
Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023) -
Severity and outcome of COVID-19 disease in patients with allergic rhinitis during the pandemic in Qatar – A preliminary report
por: Aqel, Sami, et al.
Publicado: (2022)